BIOMAT Database Logo BIOMAT Database Logo

Combined effects of treatment with trientine, a copper-chelating agent, and x-irradiation on tumor growth in transplantation model of a murine fibrosarcoma. 2007

Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Department of Veterinary Radiology, School of Veterinary Medicine, Rakuno Gakuen University, Hokkaido, Japan. hayashi@rakuno.ac.jp

Combined effects of treatment with trientine, a copper-chelating agent, and X-irradiation on development of fibrosarcoma using a murine transplantation model in vivo and on cellular survival in vitro were examined. Copper contents in the tumors and serum of trientine-treated mice were significantly lower than those of untreated mice. The tumor volumes of mouse fibrosarcoma QRsp-11 cells increased more slowly in the trientine-treated and the X-irradiated mice than in the control mice from 10 to 24 days postinoculation. The extent of inhibition of tumor growth by X-irradiation at 3 Gy was similar to that obtained by treatment with trientine. A combination of trientine and X-irradiation at 3 Gy showed inhibitory effects on tumor growth similar to those obtained by X-irradiation at 6 Gy. The results showed that trientine and X-irradiation interacted additively in inhibition of tumor growth. When QRsp-11 cells and mouse and bovine endothelial cells were treated with trientine after X-irradiation, the surviving fractions of the cells with combined treatments were essentially consistent with the products of the surviving fractions of trientine-treated cells and those of X-irradiated cells. When the cells were pretreated with trientine and X-irradiated, the surviving fractions of the pretreated cells were lower than those of cells without treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002614 Chelating Agents Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. Chelating Agent,Chelator,Complexons,Metal Antagonists,Chelators,Metal Chelating Agents,Agent, Chelating,Agents, Chelating,Agents, Metal Chelating,Antagonists, Metal,Chelating Agents, Metal
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013047 Specific Pathogen-Free Organisms Animals or humans raised in the absence of a particular disease-causing virus or other microorganism. Less frequently plants are cultivated pathogen-free. Pathogen-Free Organisms,Specific Pathogen Free,Organism, Pathogen-Free,Organism, Specific Pathogen-Free,Organisms, Pathogen-Free,Organisms, Specific Pathogen-Free,Pathogen Free Organisms,Pathogen Free, Specific,Pathogen Frees, Specific,Pathogen-Free Organism,Pathogen-Free Organism, Specific,Pathogen-Free Organisms, Specific,Specific Pathogen Free Organisms,Specific Pathogen-Free Organism
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014266 Trientine An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION. Triethylenetetramine,Syprine,Trien,Trientine Dihydrochloride,Trientine Hydrochloride

Related Publications

Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells in vivo and in vitro.
February 2007, The Journal of veterinary medical science,
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells by activation of the p38 MAPK pathway.
November 2009, The Journal of veterinary medical science,
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.
December 2001, International journal of cancer,
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Effect of X-irradiation on host-cell infiltration and growth of a murine fibrosarcoma.
May 1977, British journal of cancer,
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Effects of iron chelating agent on Schistosoma mansoni infected murine model.
January 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Multiple adjuvant therapy on a murine fibrosarcoma: actinomycin-D, X-irradiation and local tumor hyperthermia.
October 1978, Radiology,
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice.
July 2005, Oncology reports,
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Inhibition of hereditary hepatitis and liver tumor development in Long-Evans cinnamon rats by the copper-chelating agent trientine dihydrochloride.
April 1996, Hepatology (Baltimore, Md.),
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Inhibitory effects of trientine, a copper-chelating agent, on induction of DNA strand breaks in hepatic cells of Long-Evans Cinnamon rats.
November 2004, Biochimica et biophysica acta,
Masanobu Hayashi, and Ryou Hirai, and Yuusuke Ishihara, and Noboru Horiguchi, and Daiji Endoh, and Toyo Okui
Single dose X-irradiation and concomitant hyperthermia on a murine fibrosarcoma.
December 1978, Cancer,
Copied contents to your clipboard!